Clicky

Aethlon Medical, Inc.(AEMD)

Description: Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company's Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It is also developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.


Keywords: Medicine Cancer Biology Infectious Diseases Treatment Of Cancer Hepatitis Neurological Disorders Viruses Virus Antiviral Drug Coronavirus Sepsis Urological Disorders Immunodeficiency Exosome Therapeutic Device Vesicles

Home Page: www.aethlonmedical.com

AEMD Technical Analysis

11555 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 619 941 0360


Officers

Name Title
Dr. Charles J. Fisher Jr., M.D. CEO, Director & Member of Extracorporeal Therapy Advisory Board
Mr. Steven P. Larosa M.D. Chief Medical Officer & Acting Chief Scientific Officer
Mr. Guy F. Cipriani BS (Eng.), MBA Sr. VP, Chief Bus. Officer & Director
Mr. James B. Frakes M.B.A. CFO, Sr. VP of Fin. & Sec.
Mr. Sunil Sawhney Head of Clinical Studies
Dr. Richard H. Tullis Ph.D. Consultant

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0.2102
Trailing PE: 0
Price-to-Book MRQ: 0.4273
Price-to-Sales TTM: 228.4526
IPO Date: 2001-01-02
Fiscal Year End: March
Full Time Employees: 14
Back to stocks